The future of cell culture-based influenza vaccine production

References

• Barrett PN, Mundt W, Kistner O, Howard MK. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev. Vaccines8(5), 607–618 (2009).
   PubMed Web of Science ®Google Scholar
• Bernstein DI. Cell culture-derived influenza vaccines: has their time come? Clin. Infect. Dis.1(9), 1005–1006 (2010).
   Google Scholar
• Eng SZ, Jiao PR, Qi WB, Fan HY, Liao M. Development and strategies of cell-culture technology for influenza vaccine. Appl. Microbiol. Biotechnol.89(4), 893–902 (2011).
   PubMedGoogle Scholar
• Genzel Y, Reichl U. Continuous cell lines as a production system for influenza vaccines. Expert Rev. Vaccines8(12), 1681–1692 (2009).
   PubMed Web of Science ®Google Scholar
• Minor PD. Vaccines against seasonal and pandemic influenza and the implications of changes in substrates for virus production. Clin. Infect. Dis.50, 560–564 (2010).
   PubMed Web of Science ®Google Scholar
• Paillet C, Forno G, Kratje R, Etcheverrigaray M. Suspension-Vero cell cultures as a platform for viral vaccine production. Vaccine27(46), 6464–6467 (2009).
   PubMedGoogle Scholar
• Petricciani J. Cell substrates: where do we stand after 50 years of discussion? Dev. Biol. (Basel)123, 11–21; discussion 55–73 (2006).
   PubMedGoogle Scholar
• Rappuoli R. Cell-culture-based vaccine production: technological options. The Bridge36(3), 25–30 (2006).
   Google Scholar
• Cell culture as a substrate for the production of influenza vaccines: memorandum from a WHO meeting. Bull. World Health Organ.73(4), 431–435 (1995).
   PubMed Web of Science ®Google Scholar
• Chang L, Crichton R, Nandapalan P. Cell culture influenza vaccine: an Australian perspective. Dev. Biol. Stand.98, 177–181; discussion 197 (1999).
   PubMedGoogle Scholar
• Griffiths E. WHO requirements for the use of animal cells as in vitro substrates for the production of biologicals: application to influenza vaccine production. Dev. Biol. Stand.98, 153–157 (1999).
   PubMedGoogle Scholar
• Magrath DI. Safety of vaccines produced in continuous cell lines. Dev. Biol. Stand.75, 17–20 (1991).
   PubMedGoogle Scholar
• Merten OW, Manuguerra JC, Hannoun C, van der Werf S. Production of influenza virus in serum-free mammalian cell cultures. Dev. Biol. Stand.98, 23–37; discussion 73–74 (1999).
   PubMedGoogle Scholar
• Merten OW, Hannoun C, Manuguerra JC, Ventre F, Petres S. Production of influenza virus in cell cultures for vaccine preparation. Adv. Exp. Med. Biol.397, 141–151 (1996).
   PubMedGoogle Scholar
• Mills J, Van Kirk J, Hill DA, Chanock RM. Evaluation of influenza virus mutants for possible use in a live virus vaccine. Bull. World Health Organ.41(3), 599–606 (1969).
   PubMedGoogle Scholar
• Robertson JS, Cook P, Attwell AM, Williams SP. Replicative advantage in tissue culture of egg-adapted influenza virus over tissue-culture derived virus: implications for vaccine manufacture. Vaccine13(16), 1583–1588 (1995).
   PubMed Web of Science ®Google Scholar
• Tannock GA, Bryce DA, Paul JA. Evaluation of chicken kidney and chicken embryo kidney cultures for the large-scale growth of attenuated influenza virus master strain A/Ann/Arbor/6/60-ca. Vaccine3(3), 333–339 (1985).
   PubMed Web of Science ®Google Scholar
• Unanov SS, Iuminova NV. Characteristics of the immunological response in children to the administration of a live tissue-culture influenza vaccine. Vopr. Virusol.27(3), 301–305 (1982).
   PubMedGoogle Scholar
• Brands R, Visser J, Medema J, Palache AM, van Scharrenburg GJ. Influvac: a safe Madin Darby canine kidney (MDCK) cell culture-based influenza vaccine. Dev. Biol. Stand.98, 93–100 (1999).
   PubMedGoogle Scholar
• Medema JK. Wijnands DT, Abraham M. Palache The role of MDCK-based influenza vaccine Influvac® TC in (inter)pandemics. Options for the Control of Influenza V. Proceedings of the International Conference on Options for the Control of Influenza V International Congress Series1263, 822–825 (2004).
   Google Scholar
• Blume S, Geesing I. A brief history of polio vaccines. Science288(5471), 1593–1594 (2000).
   PubMedGoogle Scholar
• Montagnon BJ, Fanget B, Vincent-Falquet JC. Industrial-scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier. Rev. Infect. Dis.6(Suppl. 2), S341–S344 (1984).
   Google Scholar
• Bright RA, Carter DM, Daniluk S et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine25, 3871–3878 (2007).
   PubMed Web of Science ®Google Scholar
• Cox MM, Hollister JR. FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals37, 182–189 (2009).
   PubMed Web of Science ®Google Scholar
• Bright RA, Carter DM, Crevar CJ et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE3(1), e1501 (2008).
   PubMed Web of Science ®Google Scholar
• Haynes JR. Influenza virus-like particle vaccines. Expert Rev. Vaccines8(4), 435–445 (2009).
   PubMed Web of Science ®Google Scholar
• Kang SM, Pushko P, Bright RA, Smith G, Compans RW. Influenza virus-like particles as pandemic vaccines. Curr. Top. Microbiol. Immunol.333, 269–289 (2009).
   PubMedGoogle Scholar
• Schultz-Cherry S, Dybing JK, Davis NL et al. Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses. Virology278, 55–59 (2000).
   PubMed Web of Science ®Google Scholar
• Van Kampen KR, Shi Z, Gao P et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine23(8), 1029–1036 (2005).
   PubMed Web of Science ®Google Scholar
• Mayrhofer J, Coulibaly S, Hessel A et al. Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. J. Virol.83(10), 5192–5203 (2009).
   PubMed Web of Science ®Google Scholar
• Chichester JA, Haaheim LR, Yusibov V. Using plant cells as influenza vaccine substrates. Expert Rev. Vaccines8(4), 493–498 (2009).
   PubMed Web of Science ®Google Scholar
• Lewis JA, Brown EL, Duncan PA. Approaches to the release of a master cell bank of PER.C6 cells; a novel cell substrate for the manufacture of human vaccines. Dev. Biol. (Basel)123, 165–176; discussion 183–197 (2006).
   PubMedGoogle Scholar
• Liu J. Mani S. Schwartz R, Richman L, Tabor DE. Use of MDCK cells for production of live attenuated influenza vaccine. Vaccine27(46), 6460–6463 (2009).
   PubMed Web of Science ®Google Scholar
• Hu AY, Weng TC, Tseng YF et al. Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccine. Vaccine26(45), 5736–5740 (2008).
   PubMed Web of Science ®Google Scholar
• Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine16(9–10), 960–968 (1998).
   PubMed Web of Science ®Google Scholar
• Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine19, 2716–2721 (2001).
   PubMed Web of Science ®Google Scholar
• Matthews JT. Egg based production of influenza vaccine: 30 years of commercial experience. The Bridge36(3), 17–24 (2006).
   Google Scholar
• Soons ZI, van den IJssel J, van der Pol LA, van Straten G, van Boxtel AJ. Scaling-up vaccine production: implementation aspects of a biomass growth observer and controller. Bioprocess. Biosyst. Eng.32(3), 289–299 (2009).
   PubMedGoogle Scholar
• Tree JA, Richardson C, Fooks AR, Clegg JC, Looby D. Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine19, 3444–3450 (2001).
   PubMed Web of Science ®Google Scholar
• Frey S, Vesikari T, Szymczakiewicz-Multanowska A et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin. Infect. Dis.51(9), 997–1004 (2010).
   PubMed Web of Science ®Google Scholar
• Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial. Vaccine27(5), 786–791 (2009).
   PubMed Web of Science ®Google Scholar
• Halperin SA, Smith B, Mabrouk T et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine20(7–8), 1240–1247 (2002).
   PubMed Web of Science ®Google Scholar
• Palache AM, Brands R, van Scharrenburg GJ. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J. Infect. Dis.176(Suppl. 1), S20–S23 (1997).
   Web of Science ®Google Scholar
• Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J. Infect. Dis.200(6), 849–857 (2009).
   PubMed Web of Science ®Google Scholar
• Smith B, Mabrouk T, Germain M et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine20(7–8), 1240–1247 (2002).
   PubMedGoogle Scholar
• Szymczakiewicz-Multanowska A, Groth N, Bugarini R et al. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J. Infect. Dis.200(6), 841–848 (2009).
   PubMed Web of Science ®Google Scholar
• Cox RJ, Madhun AS, Hauge S et al. A Phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine27, 1889–1897 (2009).
   PubMed Web of Science ®Google Scholar
• Ambrozaitis A, Groth N, Bugarini R, Sparacio V, Podda A, Lattanzi M. A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine. Vaccine27(43), 6022–6029 (2009).
   PubMedGoogle Scholar
• Baylor NW, Houn F. Considerations for licensure of influenza vaccines with pandemic and prepandemic indications. Curr. Top. Microbiol. Immunol.333, 453–470 (2009).
   PubMedGoogle Scholar
• Gregersen JP. A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine. Vaccine26, 3332–3340 (2008).
   PubMed Web of Science ®Google Scholar
• Kapteyn JC, Porre AM, de Rond EJ et al. HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines. Vaccine27(9), 1468–1477 (2009).
   PubMedGoogle Scholar
• Levandowski RA. Regulatory perspective in the United States on cell cultures for production of inactivated influenza virus vaccines. Dev. Biol. Stand.98, 171–175 (1999).
   PubMedGoogle Scholar
• Minor PD, Engelhardt OG, Wood JM et al. Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine27(22), 2907–2913 (2009).
   PubMed Web of Science ®Google Scholar
• Stacey GN, Phillips P. Quality assurance for cell substrates. Dev. Biol. Stand.98, 141–151 (1999).
   PubMedGoogle Scholar
• Steel J, Lowen AC, Pena L et al. Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J. Virol.83(4), 1742–1753 (2009).
   PubMed Web of Science ®Google Scholar
• Wressnigg N, Voss D, Wolff T et al. Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate. Vaccine27(21), 2851–2857 (2009).
   PubMed Web of Science ®Google Scholar
• Audsley JM. Tannock GA. The growth of attenuated vaccine donor strains in continuous cell lines. J. Virol. Methods123(2), 187–193 (2005).
   PubMed Web of Science ®Google Scholar
• Romanova J, Katinger D, Ferko B et al. Live cold-adapted influenza A vaccine produced in Vero cell line. Virus Res.103, 187–193 (2004).
   PubMed Web of Science ®Google Scholar
• Ghendon YZ, Markushin SG, Akopova II et al. Development of cell culture (MDCK) live cold-adapted (CA) attenuated influenza vaccine Vaccine23(38), 4678–4684 (2005).
   PubMed Web of Science ®Google Scholar
• Atmar RL. Emerging trends: vaccines in late development. Int. J. Infect. Dis.14, e13 (2010).
   Google Scholar
• Edwards KM, Sabow A, Pasternak A, Boslego JW. Strategies for broad global access to pandemic influenza vaccines. Curr. Top. Microbiol. Immunol.333, 471–493 (2009).
   PubMedGoogle Scholar
• Kreijtz JH, Osterhaus AD, Rimmelzwaan GF. Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control. Hum. Vaccin.5(3), 126–135 (2009).
   PubMed Web of Science ®Google Scholar
• Perdue ML, Bright R. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world. Vaccine29(Suppl. 1), A48–A50 (2011).
   PubMedGoogle Scholar
• Chu C, Lugovtsev V, Golding H, Betenbaugh M, Shiloach J. Conversion of MDCK cell line to suspension culture by transfecting with human siat7e gene and its application for influenza virus production. Proc. Natl Acad. Sci USA106(35), 14802–14807 (2009).
   PubMedGoogle Scholar
• Genzel Y, Olmer RM, Schäfer B, Reichl U. Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media. Vaccine24(35–36), 6074–6087 (2006).
   PubMed Web of Science ®Google Scholar
• Hussain AI, Cordeiro M, Sevilla E, Liu J. Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells. Vaccine28(22), 3848–3855 (2010).
   PubMed Web of Science ®Google Scholar
• Murakami S, Horimoto T, Mai le Q et al. Growth determinants for H5N1 influenza vaccine seed viruses in MDCK cells. J. Virol.82(21), 10502–10509 (2008).
   PubMed Web of Science ®Google Scholar
• Schwarzer J, Rapp E, Hennig R et al. Glycan analysis in cell culture-based influenza vaccine production: influence of host cell line and virus strain on the glycosylation pattern of viral hemagglutinin. Vaccine27(32), 4325–4336 (2009).
   PubMed Web of Science ®Google Scholar
• Smith KA, Colvin CJ, Weber PS, Spatz SJ, Coussens PM. High titer growth of human and avian influenza viruses in an immortalized chick embryo cell line without the need for exogenous proteases. Vaccine26, 3778–3782 (2008).
   PubMed Web of Science ®Google Scholar
• United States Government Accountability Office. Influenza Pandemic: Sustaining Focus on the Nation’s Planning and Preparedness. Report No.: GAO-09–334. Government Accountability Office, Washington DC, USA (2009).
   Google Scholar
• Barrett PN, Portsmouth D, Ehrlich HJ. Developing cell culture-derived pandemic vaccines. Curr. Opin. Mol. Ther.12(1), 21–30 (2010).
   PubMedGoogle Scholar
• Crowe BA, Brühl P, Gerencer M et al. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans. Vaccine29(2), 166–173 (2010).
   PubMed Web of Science ®Google Scholar
• Doroshenko A, Halperin SA. Trivalent MDCK cell culture derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev. Vaccines8, 679–688 (2009).
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Müller M, Oh HM et al.; Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med.358, 2573–2584 (2008).
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Müller M, Fritsch S et al. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J. Infect. Dis.200(7), 1113–1118 (2009).
   PubMed Web of Science ®Google Scholar
• Howard MK, Kistner O, Barrett PN. Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biol. Chem.389(5), 569–577 (2008).
   PubMed Web of Science ®Google Scholar
• Kistner O, Howard MK, Spruth M et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine25(32), 6028–6036 (2007).
   PubMed Web of Science ®Google Scholar
• Liu J, Mani S, Schwartz R, Richman L, Tabor DE. Cloning and assessment of tumorigenicity and oncogenicity of a Madin–Darby canine kidney (MDCK) cell line for influenza vaccine production. Vaccine28(5), 1285–1293 (2010).
   PubMed Web of Science ®Google Scholar
• Guan Y, Smith GJ, Webby R, Webster RG. Molecular epidemiology of H5N1 avian influenza. Rev. Sci. Tech.28(1), 39–47 (2009).
   PubMed Web of Science ®Google Scholar
• Keitel W, Groth N, Lattanzi M et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a Phase 1/2 clinical trial. Vaccine28(3), 840–848 (2010).
   PubMed Web of Science ®Google Scholar
• Keitel WA, Dekker CL, Mink C et al. Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Vaccine27(47), 6642–6648 (2009).
   PubMed Web of Science ®Google Scholar
• Partridge J, Kieny MP; World Health Organization H1N1 influenza vaccine Task Force. Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009–2010 and comparison with previous estimates and global action plan targets. Vaccine28(30), 4709–4712 (2010).
   PubMed Web of Science ®Google Scholar
• Neuzil KM, Bright RA. Influenza vaccine manufacture: keeping up with change. J. Infect. Dis.200(6), 835–837 (2009).
   PubMed Web of Science ®Google Scholar
• Henkle E, Steinhoff MC, Omer SB et al. Incidence of influenza virus infection in early infancy: a prospective study in south Asia. Pediatr. Infect. Dis. J.30(2), 170–173 (2010).
   Google Scholar
• Brooks WA, Goswami D, Rahman M et al. Influenza is a major contributor to childhood pneumonia in a tropical developing country. Pediatr. Infect. Dis. J.29(3), 216–221 (2010).
   PubMedGoogle Scholar
• Meena G, Farooq M, Dang et al. Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process. Biotechnol. Bioeng.106(6), 906–917 (2010).
   PubMedGoogle Scholar